The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide ...
Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...
Hims & Hers Health (NYSE:HIMS) is down 7% in early morning trading after the U.S. FDA determined that there is no shortage of ...
THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of ...
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...
Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...
Credit: Eli Lilly. Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss). Compounding pharmacies must now cease producing the lucrative ...
Tirzepatide includes injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss). The FDA first announced 2 months ago that any shortage of the medications observed during ...